Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 5,585 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 5,585 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.49, for a total value of $19,491.65. Following the completion of the sale, the chief executive officer now directly owns 3,039,194 shares of the company’s stock, valued at $10,606,787.06. The trade was a 0.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Organogenesis Stock Down 9.2 %

Shares of NASDAQ ORGO opened at $3.24 on Thursday. The firm has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $3.01. Organogenesis Holdings Inc. has a 12 month low of $2.16 and a 12 month high of $4.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $429.55 million, a PE ratio of -54.00 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same quarter in the previous year, the company earned $0.02 earnings per share. Equities analysts expect that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after buying an additional 333,123 shares during the period. Wealth Dimensions Group Ltd. boosted its holdings in shares of Organogenesis by 435.9% during the 2nd quarter. Wealth Dimensions Group Ltd. now owns 407,965 shares of the company’s stock valued at $1,142,000 after buying an additional 331,840 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Organogenesis by 1,350.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock worth $265,000 after buying an additional 88,175 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock worth $8,605,000 after acquiring an additional 72,696 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.